In GPR119‐deficient NAFPD mice, terazosin failed to induce the beneficial effects observed in regular NAFPD mice, including improvements in obesity, hyperglycemia, and insulin sensitivity, as well as the increase of β‐cell functional gene expression in the pancreas. This evidence concerns the gene INS and Hyperglycemia.